PTGS1 and ulcer disease: In contrast, low-dose aspirin-induced ulcers, while also involving Cyclooxygenase 1 inhibition, primarily present a risk due to the continuous antiplatelet effect, often requiring careful balancing of gastrointestinal protection with the cardiovascular benefits of aspirin, making the choice of protective agents, such as PPIs or vonoprazan, and their dosage particularly critical in preventing ulcer recurrence.